Wiskott-Aldrich Syndrome Clinical Trial
Official title:
Phase I/II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome
Wiskott-Aldrich syndrome (WAS) is a rare X-linked congenital immune-deficiency syndrome and hematopoietic stem cell transplantation (HSCT) has become a curative modality. But the transplant with the conventional conditioning resulted in high incidence of treatment related toxicities and non-myeloablative conditioning resulted in high incidence of engraftment failure. Recently, fludarabine based reduced toxicity myeloablative conditioning regimen was developed for adult myeloid malignancies with promising result of good engraftment and low treatment related toxicities. To increase the engraftment potential without serious complication, reduced toxicity myeloablative conditioning regimen composed of fludarabine, busulfan, and thymoglobulin is designed for Wiskott-Aldrich syndrome.
Wiskott-Aldrich syndrome (WAS) is an rare X-linked congenital immune-deficiency syndrome
characterized by the triad of recurrent infection, eczema and thrombocytopenia with small
size of platelet (Puck JM, 2006). Clinical studies revealed high rate of autoimmune disorder
and malignancy in WAS (Ochs HD, 2006). The identification of the molecular defect in 1994
(Derry JM, 1994) has broadened the clinical spectrum of the syndrome to include chronic or
intermittent X-linked thrombocytopenia (XLT), a relatively mild form of WAS and X-lined
neutropenia caused by an arrest of myelopoiesis (Ochs HD, 2006).
The incidence of WAS in Korea was very low and only 6 patients diagnosed between 2001 and
2005 (Kim JG, 2006).
Conventional treatments for WAS such as prophylactic antibiotics and immune globin for
infection and platelet transfusion for bleeding were not so successful (Thrasher AJ, 2000).
Bone marrow transplantation (BMT) from an HLA-matched related donor is an effective
treatment (Filipovich AH, 2001) and patients without appropriate related donor could receive
alternative stem cell source such as matched unrelated donor or cord blood. But the
transplant with the alternative donor needed more intensive conditioning to overcome the
hematologic and immunologic barrier with increased treatment related toxicity. Further
progress depends in particular on the development of alternative preparative conditioning
regimens which allow stable engraftment of donor precursor cells with minimal systemic toxic
side effects (Friedrich W, 2004).
Recently, we reported successful unrelated bone marrow transplantation in a boy with WAS
with reduced toxicity myeloablative conditioning regimen to increase the engraftment
potential without serious complication (Kang, 2008), and extended to multicenter phase I/II
pilot study with this reduced toxicity myeloablative conditioning regimen in the HSCT for
WAS.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
Completed |
NCT01953016 -
Participation in a Research Registry for Immune Disorders
|
||
Active, not recruiting |
NCT02333760 -
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
|
Phase 1/Phase 2 | |
Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT04371939 -
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
|
Phase 2 | |
Completed |
NCT01347346 -
Gene Therapy for WAS
|
Phase 1/Phase 2 | |
Completed |
NCT00160355 -
Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome
|
Phase 1 | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Completed |
NCT01289847 -
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
|
Phase 4 | |
Completed |
NCT01347242 -
Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
|
Phase 1/Phase 2 | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Enrolling by invitation |
NCT03198195 -
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
|
N/A | |
Recruiting |
NCT03019809 -
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
|
Phase 2 | |
Terminated |
NCT00909363 -
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
|
Phase 2 | |
Enrolling by invitation |
NCT01852370 -
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
|
Phase 1/Phase 2 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01410825 -
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00004341 -
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
|
N/A | |
Completed |
NCT03399461 -
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
|